questionText: To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the requirement in the NHS England Commercial Framework for New Medicines for medicines to provide value at-or-below NICE’s cost-effectiveness threshold on access to treatments for (a) rare and (b) ultra-rare disease patients .
answerText: I refer the Hon. Member to the answers my Rt Hon. Friend, the Minister of State for Health gave on 1 September 2025 to Questions 69240, 69241, and 69242.
heading: Rare Diseases: Drugs